IL186604A0 - Therapeutic combination in case of benign prostate hyperplasia - Google Patents

Therapeutic combination in case of benign prostate hyperplasia

Info

Publication number
IL186604A0
IL186604A0 IL186604A IL18660407A IL186604A0 IL 186604 A0 IL186604 A0 IL 186604A0 IL 186604 A IL186604 A IL 186604A IL 18660407 A IL18660407 A IL 18660407A IL 186604 A0 IL186604 A0 IL 186604A0
Authority
IL
Israel
Prior art keywords
case
therapeutic combination
benign prostate
prostate hyperplasia
hyperplasia
Prior art date
Application number
IL186604A
Other languages
English (en)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of IL186604A0 publication Critical patent/IL186604A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL186604A 2005-04-13 2007-10-11 Therapeutic combination in case of benign prostate hyperplasia IL186604A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005016981A DE102005016981A1 (de) 2005-04-13 2005-04-13 Kombination zur Therapie bei benigner Prostatahyperplasie
PCT/EP2006/002941 WO2006108519A1 (de) 2005-04-13 2006-03-31 Kombination zur therapie bei benigner prostatahyperplasie

Publications (1)

Publication Number Publication Date
IL186604A0 true IL186604A0 (en) 2008-01-20

Family

ID=36608700

Family Applications (1)

Application Number Title Priority Date Filing Date
IL186604A IL186604A0 (en) 2005-04-13 2007-10-11 Therapeutic combination in case of benign prostate hyperplasia

Country Status (22)

Country Link
EP (1) EP1888075A1 (zh)
JP (1) JP2008535877A (zh)
KR (1) KR20080007252A (zh)
CN (1) CN101193638A (zh)
AR (1) AR053575A1 (zh)
AU (1) AU2006233567A1 (zh)
BR (1) BRPI0610634A2 (zh)
CA (1) CA2605224A1 (zh)
CR (1) CR9427A (zh)
DE (1) DE102005016981A1 (zh)
DO (1) DOP2006000074A (zh)
GT (1) GT200600145A (zh)
IL (1) IL186604A0 (zh)
MA (1) MA29683B1 (zh)
MX (1) MX2007012567A (zh)
PE (1) PE20061338A1 (zh)
RU (1) RU2007141518A (zh)
SV (1) SV2008002477A (zh)
TN (1) TNSN07385A1 (zh)
TW (1) TW200716122A (zh)
UY (1) UY29473A1 (zh)
WO (1) WO2006108519A1 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
EP1968705A1 (en) * 2005-12-21 2008-09-17 Pfizer Products Incorporated Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
RU2009103660A (ru) * 2006-07-07 2010-08-20 Тева Фармасьютикал Индастриес Лтд. (Il) Твердые фармацевтические композиции, включающие тадалафил и по меньшей мере один носитель
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
PL2222300T3 (pl) 2007-12-13 2015-02-27 Vanda Pharmaceuticals Inc Sposób i skład preparatu do leczenia chorób z udziałem receptorów serotoniny
ES2527515T3 (es) 2007-12-13 2015-01-26 Vanda Pharmaceuticals Inc. Método y composición para tratar una afección mediada por un adrenoceptor alfa
US8885621B2 (en) 2010-04-26 2014-11-11 Intel Corporation Method, apparatus and system for switching traffic streams among multiple bands
WO2013123965A1 (en) * 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
CN102727456B (zh) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 药物口腔崩解片及其制备方法
BR112015032728A2 (pt) * 2013-06-28 2017-07-25 Hanmi Pharm Ind Co Ltd formulação compósita em cápsula farmacêutica compreendendo tadalafil e tansulosina
CA2919198A1 (en) 2013-07-23 2015-01-29 Allergan, Inc. Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist
KR101663238B1 (ko) * 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
WO2016003180A1 (ko) * 2014-06-30 2016-01-07 한미약품 주식회사 5-α-환원효소 억제제-함유 필름 코팅층을 포함하는 복합제제 및 그 제조방법
BR112016030731A2 (pt) * 2014-06-30 2017-08-22 Hanmi Pharm Ind Co Ltd Preparação de compósito, e, método de preparação de uma preparação de compósito
EP3162363B1 (en) * 2014-06-30 2020-01-08 Hanmi Pharm. Co., Ltd. Composite preparation comprising active ingredient-containing film coating layer
EP3220942B1 (en) * 2014-11-20 2022-04-27 Serenity Pharmaceuticals LLC Compositions comprising low dose desmopressin in combination with an alpha-adrenergic receptor antagonist
BR112018069852A2 (pt) * 2016-03-31 2019-01-29 Hanmi Pharm Ind Co Ltd formulação compósita de cápsula e método para preparar a formulação compósita de cápsula
KR101835506B1 (ko) * 2016-10-25 2018-03-07 주식회사 에스텍파마 두타스테리드와 타다라필을 함유하는 속효성 복합정제
CN108066347B (zh) * 2016-11-16 2021-02-02 深圳万和制药有限公司 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物
KR101879133B1 (ko) * 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
TR201715231A2 (tr) * 2017-10-09 2019-04-22 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Also Published As

Publication number Publication date
KR20080007252A (ko) 2008-01-17
JP2008535877A (ja) 2008-09-04
EP1888075A1 (de) 2008-02-20
UY29473A1 (es) 2006-11-30
DOP2006000074A (es) 2006-10-15
BRPI0610634A2 (pt) 2010-07-13
MA29683B1 (fr) 2008-08-01
MX2007012567A (es) 2007-12-10
DE102005016981A1 (de) 2006-10-19
CR9427A (es) 2007-12-17
SV2008002477A (es) 2008-02-08
CA2605224A1 (en) 2006-10-19
RU2007141518A (ru) 2009-05-20
GT200600145A (es) 2007-04-10
CN101193638A (zh) 2008-06-04
PE20061338A1 (es) 2007-01-28
WO2006108519A1 (de) 2006-10-19
AU2006233567A1 (en) 2006-10-19
AR053575A1 (es) 2007-05-09
TNSN07385A1 (en) 2009-03-17
TW200716122A (en) 2007-05-01

Similar Documents

Publication Publication Date Title
IL186604A0 (en) Therapeutic combination in case of benign prostate hyperplasia
EP1959855A4 (en) TREATMENT OF BENIGN PROSTATIC HYPERTROPHY USING PHOTOSENSITIZER AND LASER ABLATION
EP1967209A4 (en) THERAPEUTIC AGENT AGAINST PROSTATE CANCER
HK1215683A1 (zh) 抗葉酸藥在癌症治療中的聯合應用
IL182533A0 (en) Prostate treatment stent
IL181608A0 (en) Cancer combination therapy comprising azd2171 and imatinib
HK1199874A1 (zh) 螺吲哚化合物及其作爲治療劑的應用
EP1887976B8 (en) Devices for treating benign prostatic hyperplasia and other conditions
HK1136822A1 (en) Therapeutic compounds and their use in cancer
IL191072A0 (en) Therapeutic compositions and methods
IL186615A0 (en) Spiroheterocylic compounds and their uses as therapeutic agents
EP1876186A4 (en) PROPHYLACTIC / THERAPEUTIC AGENT FOR CANCER
IL188430A0 (en) Treatment of tumors
PT2275103E (pt) Inibidores de mtor para o tratamento de tumores endócrinos
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
PL2559439T3 (pl) Preparat farmaceutyczny do leczenia łagodnego rozrostu gruczołu krokowego
EP2025347A4 (en) PROPHYLACTIC AND THERAPEUTIC AGENTS AGAINST CANCER
EP1812596A4 (en) TREATMENT OF CANCER AND COMPOSITIONS
EP1756166A4 (en) DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
EP2083840A4 (en) IMPROVED TREATMENT FOR BENEFICIAL PROSTATE HYPERPLASIA
HK1105288A1 (en) Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
EP1904088A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
IL194463A0 (en) Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound
IL185575A0 (en) Benzoxazocines and their therapeutic use